Axent Biosciences key facts
- Developer of stem cell therapies designed to address unmet medical needs in human health.
- Axent Biosciences’s last known valuation is $38.0M.
- It has raised $17.2M; the latest was Seed Round ($6.0M) in Sep 2024.
- Notable investors include Berkeley SkyDeck, Berkeley Frontier Fund, venBio, Berkeley SkyDeck Fund, Kerna Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Axent Biosciences: the Monday email on marks, rounds and moves
Axent Biosciences funding rounds
No funding rounds for Axent Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Axent Biosciences valuation
Axent Biosciences's last known valuation is $38 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Axent Biosciences investors
8 investors are on record for Axent Biosciences, including Berkeley SkyDeck, Berkeley Frontier Fund, venBio and Berkeley SkyDeck Fund.
About Axent Biosciences
Developer of stem cell therapies designed to address unmet medical needs in human health. The company's platform uses technology in stem cell manufacturing and implantation to leverage years of stem cell and biomaterials engineering expertise to overcome major bottlenecks in the clinical development pipeline, enabling patients in need with stem cell therapeutics.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 10
- Website
- axentbiosciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Axent Biosciences’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.